Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2019 Jun;11(6):E82-E85.
doi: 10.21037/jtd.2019.06.11.

Epithelial-to-mesenchymal transition and drug resistance: transitioning away from death

Kyung-A Song  1 , Anthony C Faber  1
Affiliations
Comment

Epithelial-to-mesenchymal transition and drug resistance: transitioning away from death

Kyung-A Song et al. J Thorac Dis. 2019 Jun.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: AC Faber has served as a paid consultant for AbbVie. KA Song has no conflicts of interest to declare.

Figures

Figure 1
Figure 1
How EMT suppresses apoptosis. The EMT transcription factors (ZEB1 and TWIST1) can directly bind to the promoter and intronic regions of the pro-apoptotic BH3-only gene, BCL2L11 (BIM). Navitoclax (ABT-263) is a potential therapeutic strategy for de-repressing the available cellular BIM in the cell, to re-sensitize EMT EGFR mutant lung cancer cells and other EMT cancers. Alternatively, directly targeting the EMT transcription repressors, like with harmine, can reverse EMT resistance as well. EMT, epithelial-to-mesenchymal transition.
See this image and copyright information in PMC

Comment on

References

    1. Popper HH. Progression and metastasis of lung cancer. Cancer Metastasis Rev 2016;35:75-91. 10.1007/s10555-016-9618-0 - DOI - PMC - PubMed
    1. Qi XK, Han HQ, Zhang HJ, et al. OVOL2 links stemness and metastasis via fine-tuning epithelial-mesenchymal transition in nasopharyngeal carcinoma. Theranostics 2018;8:2202-16. 10.7150/thno.24003 - DOI - PMC - PubMed
    1. Deep G, Agarwal R. Antimetastatic efficacy of silibinin: molecular mechanisms and therapeutic potential against cancer. Cancer Metastasis Rev 2010;29:447-63. 10.1007/s10555-010-9237-0 - DOI - PMC - PubMed
    1. Song KA, Niederst MJ, Lochmann TL, et al. Epithelial-to-Mesenchymal Transition Antagonizes Response to Targeted Therapies in Lung Cancer by Suppressing BIM. Clin Cancer Res 2018;24:197-208. 10.1158/1078-0432.CCR-17-1577 - DOI - PMC - PubMed
    1. Zeisberg M, Neilson EG. Biomarkers for epithelial-mesenchymal transitions. J Clin Invest 2009;119:1429-37. 10.1172/JCI36183 - DOI - PMC - PubMed